Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Pipeline Review, H1 2018’, provides in depth analysis on Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Oncology, Women's Health and Respiratory under development targeting Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

– The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

CJ HealthCare Corp

MorphoSys AG

Novartis AG

Vicore Pharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Overview

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Companies Involved in Therapeutics Development

CJ HealthCare Corp

MorphoSys AG

Novartis AG

Vicore Pharma AB

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Drug Profiles

(amlodipine besylate + valsartan)+ atorvastatin calcium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-21 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDT-501 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOR-107 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-6A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olodanrigan Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Dormant Products

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Discontinued Products

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Product Development Milestones

Featured News & Press Releases

Mar 21, 2018: Frontiers in Physiology publish data with C21 on pulmonary fibrosis

Jan 26, 2018: Highlights from new publications on C21 and the AT2 receptor

Dec 22, 2017: Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis

Oct 09, 2017: Clinical Potential of C21 Highlighted in Review Publications

Oct 02, 2017: Phase I extension study demonstrates beneficial effects on lipid metabolism with C21

Aug 17, 2017: Results from Extension Study with C21 Show Safety, Tolerability and Indicate Effects on lipid Metabolism

May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers

Mar 08, 2017: C21 has a strong impact on several markers in an in vitro study for pulmonary fibrosis

Mar 03, 2017: New positive study results on diabetic nephropathy with Vicore Pharma's candidate drug C21

Feb 21, 2017: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107

Feb 15, 2017: Vicore Pharma extends research portfolio with new drug molecules

Sep 19, 2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSys’s Dutch Lanthipeptide Subsidiary

Aug 01, 2016: Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF

Jun 30, 2016: New research data with C21 on diabetes

Jun 15, 2016: Prestigious award for UQ superstar scientist

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by CJ HealthCare Corp, H1 2018

Pipeline by MorphoSys AG, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Vicore Pharma AB, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports